Phosphodiesterase-4 Inhibition in Psoriasis

Milica Milakovic,1 Melinda J Gooderham2– 4 1Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Skin Centre for Dermatology, Peterborough, ON, K9J 5K2, Canada; 3Probity Medical Research, Waterloo, ON, N2J 1C4, Canada; 4Department of Medicine, Queen’s University, Kin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Milakovic M, Gooderham MJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	psoriasis pde-4 phosphodiesterase inhibitors topical therapies Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/ab2d804e082e400694d7b6fb14a36246
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab2d804e082e400694d7b6fb14a36246
record_format	dspace
spelling	oai:doaj.org-article:ab2d804e082e400694d7b6fb14a362462021-12-02T16:27:46ZPhosphodiesterase-4 Inhibition in Psoriasis2230-326Xhttps://doaj.org/article/ab2d804e082e400694d7b6fb14a362462021-03-01T00:00:00Zhttps://www.dovepress.com/phosphodiesterase-4-inhibition-in-psoriasis-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XMilica Milakovic,1 Melinda J Gooderham2– 4 1Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Skin Centre for Dermatology, Peterborough, ON, K9J 5K2, Canada; 3Probity Medical Research, Waterloo, ON, N2J 1C4, Canada; 4Department of Medicine, Queen’s University, Kingston, ON, K7L 3N6, CanadaCorrespondence: Melinda J GooderhamSkin Centre for Dermatology, 775 Monaghan Road, Peterborough, ON, K9J 5K2, CanadaTel +1 705 775 7546Fax +1 705 775 3376Email mgooderham@centrefordermatology.comAbstract: Psoriasis is a chronic immune-mediated inflammatory disorder. Phosphodiesterase-4 (PDE-4) is an enzyme that mediates inflammatory responses and plays a role in psoriasis pathogenesis. PDE-4 degrades its substrate cyclic adenosine monophosphate (cAMP) to adenosine monophosphate (AMP), which subsequently leads to the production of pro-inflammatory mediators. Inhibitors of PDE-4 work by blocking the degradation of cAMP, which leads to a reduction in inflammation. Apremilast is the only approved oral PDE-4 inhibitor for the treatment of psoriasis. While it is effective for some patients, it may be limited by adverse effects in others. A topical PDE-4 inhibitor, roflumilast, is being investigated in psoriasis and showing promising results. Crisaborole, a topical PDE-4 inhibitor approved for use in atopic dermatitis, has also been investigated in psoriasis. This is an updated comprehensive review to summarize the currently available evidence for the PDE-4 inhibitors apremilast, roflumilast and crisaborole in the treatment of psoriasis, with a focus on data from randomized clinical trials.Keywords: psoriasis, PDE-4, phosphodiesterase inhibitors, topical therapiesMilakovic MGooderham MJDove Medical Pressarticlepsoriasispde-4phosphodiesterase inhibitorstopical therapiesDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 11, Pp 21-29 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	psoriasis pde-4 phosphodiesterase inhibitors topical therapies Dermatology RL1-803
spellingShingle	psoriasis pde-4 phosphodiesterase inhibitors topical therapies Dermatology RL1-803 Milakovic M Gooderham MJ Phosphodiesterase-4 Inhibition in Psoriasis
description	Milica Milakovic,1 Melinda J Gooderham2– 4 1Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Skin Centre for Dermatology, Peterborough, ON, K9J 5K2, Canada; 3Probity Medical Research, Waterloo, ON, N2J 1C4, Canada; 4Department of Medicine, Queen’s University, Kingston, ON, K7L 3N6, CanadaCorrespondence: Melinda J GooderhamSkin Centre for Dermatology, 775 Monaghan Road, Peterborough, ON, K9J 5K2, CanadaTel +1 705 775 7546Fax +1 705 775 3376Email mgooderham@centrefordermatology.comAbstract: Psoriasis is a chronic immune-mediated inflammatory disorder. Phosphodiesterase-4 (PDE-4) is an enzyme that mediates inflammatory responses and plays a role in psoriasis pathogenesis. PDE-4 degrades its substrate cyclic adenosine monophosphate (cAMP) to adenosine monophosphate (AMP), which subsequently leads to the production of pro-inflammatory mediators. Inhibitors of PDE-4 work by blocking the degradation of cAMP, which leads to a reduction in inflammation. Apremilast is the only approved oral PDE-4 inhibitor for the treatment of psoriasis. While it is effective for some patients, it may be limited by adverse effects in others. A topical PDE-4 inhibitor, roflumilast, is being investigated in psoriasis and showing promising results. Crisaborole, a topical PDE-4 inhibitor approved for use in atopic dermatitis, has also been investigated in psoriasis. This is an updated comprehensive review to summarize the currently available evidence for the PDE-4 inhibitors apremilast, roflumilast and crisaborole in the treatment of psoriasis, with a focus on data from randomized clinical trials.Keywords: psoriasis, PDE-4, phosphodiesterase inhibitors, topical therapies
format	article
author	Milakovic M Gooderham MJ
author_facet	Milakovic M Gooderham MJ
author_sort	Milakovic M
title	Phosphodiesterase-4 Inhibition in Psoriasis
title_short	Phosphodiesterase-4 Inhibition in Psoriasis
title_full	Phosphodiesterase-4 Inhibition in Psoriasis
title_fullStr	Phosphodiesterase-4 Inhibition in Psoriasis
title_full_unstemmed	Phosphodiesterase-4 Inhibition in Psoriasis
title_sort	phosphodiesterase-4 inhibition in psoriasis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/ab2d804e082e400694d7b6fb14a36246
work_keys_str_mv	AT milakovicm phosphodiesterase4inhibitioninpsoriasis AT gooderhammj phosphodiesterase4inhibitioninpsoriasis
_version_	1718384010304946176

Phosphodiesterase-4 Inhibition in Psoriasis

Ejemplares similares